{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T22:15:06Z","timestamp":1773526506750,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.canlet.2021.10.022","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T07:59:18Z","timestamp":1634889558000},"page":"206-218","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Repressing MYC by targeting BET synergizes with selective inhibition of PI3K\u03b1 against B cell lymphoma"],"prefix":"10.1016","volume":"524","author":[{"given":"Zi-qi","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe-rui","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-xiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-hao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling-hua","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6769","key":"10.1016\/j.canlet.2021.10.022_bib1","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.canlet.2021.10.022_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2013.12.012","article-title":"SnapShot: diffuse large B cell lymphoma","volume":"25","author":"Pasqualucci","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2021.10.022_bib3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.critrevonc.2017.02.027","article-title":"The role of anti-PD-1 and anti-PD-L1 agents in the treatment of diffuse large B-cell lymphoma: the future is now","volume":"113","author":"Ju\u00e1rez-Salcedo","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"8","key":"10.1016\/j.canlet.2021.10.022_bib4","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/blood-2018-04-839217","article-title":"Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed\/refractory diffuse large B-cell lymphoma","volume":"132","author":"Chow","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.canlet.2021.10.022_bib5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/13543784.2021.1855140","article-title":"Investigational drugs for the treatment of diffuse large B-cell lymphoma","volume":"30","author":"Patriarca","year":"2021","journal-title":"Expet Opin. Invest. Drugs"},{"issue":"10","key":"10.1016\/j.canlet.2021.10.022_bib6","doi-asserted-by":"crossref","first-page":"5715","DOI":"10.4049\/jimmunol.176.10.5715","article-title":"Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma","volume":"176","author":"Gururajan","year":"2006","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.canlet.2021.10.022_bib7","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1084\/jem.20020805","article-title":"A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation","volume":"196","author":"Clayton","year":"2002","journal-title":"J. Exp. Med."},{"issue":"47","key":"10.1016\/j.canlet.2021.10.022_bib8","doi-asserted-by":"crossref","first-page":"81794","DOI":"10.18632\/oncotarget.20864","article-title":"PI3Kdelta inhibition causes feedback activation of PI3Kalpha in the ABC subtype of diffuse large B-cell lymphoma","volume":"8","author":"Pongas","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.canlet.2021.10.022_bib9","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ccell.2016.12.003","article-title":"Simultaneous inhibition of PI3K\u03b4 and PI3K\u03b1 induces ABC-DLBCL regression by blocking BCR-dependent and -independent activation of NF-\u03baB and AKT","volume":"31","author":"Paul","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2021.10.022_bib10","article-title":"SAF-248, a novel PI3Kdelta-selective inhibitor, potently suppresses the growth of diffuse large B-cell lymphoma","author":"Zhang","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"issue":"4","key":"10.1016\/j.canlet.2021.10.022_bib11","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1182\/blood-2002-07-2009","article-title":"Cell cycle deregulation in B-cell lymphomas","volume":"101","author":"S\u00e1nchez-Beato","year":"2003","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.canlet.2021.10.022_bib12","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.3324\/haematol.2013.086173","article-title":"MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"98","author":"Valera","year":"2013","journal-title":"Haematologica"},{"issue":"20","key":"10.1016\/j.canlet.2021.10.022_bib13","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","article-title":"Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab","volume":"28","author":"Barrans","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.canlet.2021.10.022_bib14","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2021.10.022_bib15","doi-asserted-by":"crossref","first-page":"102154","DOI":"10.1016\/j.ctrv.2021.102154","article-title":"MYC as a target for cancer treatment","volume":"94","author":"Duffy","year":"2021","journal-title":"Cancer Treat Rev."},{"issue":"1","key":"10.1016\/j.canlet.2021.10.022_bib16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","article-title":"MYC on the path to cancer","volume":"149","author":"Dang","year":"2012","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.canlet.2021.10.022_bib17","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1093\/annonc\/mdx157","article-title":"BET inhibitors: a novel epigenetic approach","volume":"28","author":"Doroshow","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2021.10.022_bib18","doi-asserted-by":"crossref","first-page":"112913","DOI":"10.1016\/j.ejmech.2020.112913","volume":"209","author":"Xiang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.canlet.2021.10.022_bib19","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.canlet.2018.07.011","article-title":"Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3K alpha-selective inhibitor CYH33 in breast cancer","volume":"433","author":"Liu","year":"2018","journal-title":"Cancer Lett."},{"issue":"8","key":"10.1016\/j.canlet.2021.10.022_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003093","article-title":"PI3Kalpha inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8(+)T cells and promoting fatty acid metabolism","volume":"9","author":"Sun","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2021.10.022_bib21","doi-asserted-by":"crossref","first-page":"66","DOI":"10.20892\/j.issn.2095-3941.2018.0361","article-title":"Simultaneous inhibition of PI3Kalpha and CDK4\/6 synergistically suppresses KRAS-mutated non-small cell lung cancer","volume":"16","author":"Wang","year":"2019","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.canlet.2021.10.022_bib22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.canlet.2019.05.040","article-title":"PI3Kalpha inhibitors sensitize esophageal squamous cell carcinoma to radiation by abrogating survival signals in tumor cells and tumor microenvironment","volume":"459","author":"Shi","year":"2019","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.canlet.2021.10.022_bib23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41419-020-03370-4","article-title":"Adaptive resistance to PI3Kalpha-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells","volume":"12","author":"Wang","year":"2021","journal-title":"Cell Death Dis."},{"issue":"7","key":"10.1016\/j.canlet.2021.10.022_bib24","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1021\/acs.jmedchem.6b01502","article-title":"6-OH-Phenanthroquinolizidine alkaloid and its derivatives exert potent anticancer activity by delaying S phase progression","volume":"60","author":"Liu","year":"2017","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.canlet.2021.10.022_bib25","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"issue":"W1","key":"10.1016\/j.canlet.2021.10.022_bib26","doi-asserted-by":"crossref","first-page":"W98","DOI":"10.1093\/nar\/gkx247","article-title":"GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses","volume":"45","author":"Tang","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"10.1016\/j.canlet.2021.10.022_bib27","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.canlet.2021.10.022_bib28","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1182\/blood-2013-02-483727","article-title":"Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing","volume":"122","author":"Morin","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.canlet.2021.10.022_bib29","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1073\/pnas.1121343109","article-title":"Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing","volume":"109","author":"Lohr","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.canlet.2021.10.022_bib30","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and functional drivers of diffuse large B cell lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"issue":"45","key":"10.1016\/j.canlet.2021.10.022_bib31","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Bea","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.canlet.2021.10.022_bib32","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/aps.2013.81","article-title":"A pharmacological model reveals biased dependency on PI3K isoforms for tumor cell growth","volume":"34","author":"Wang","year":"2013","journal-title":"Acta Pharmacol. Sin."},{"issue":"1","key":"10.1016\/j.canlet.2021.10.022_bib33","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1182\/blood-2004-01-0240","article-title":"The phosphodiesterase PDE4B limits cAMP-associated PI3K\/AKT-dependent apoptosis in diffuse large B-cell lymphoma","volume":"105","author":"Smith","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.canlet.2021.10.022_bib34","doi-asserted-by":"crossref","first-page":"66","DOI":"10.20892\/j.issn.2095-3941.2018.0361","article-title":"Simultaneous inhibition of PI3K\u03b1 and CDK4\/6 synergistically suppresses KRAS-mutated non-small cell lung cancer","volume":"16","author":"Wang","year":"2019","journal-title":"Cancer Biol Med"},{"issue":"5","key":"10.1016\/j.canlet.2021.10.022_bib35","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1172\/JCI79134","article-title":"Telomerase regulates MYC-driven oncogenesis independent of its reverse transcriptase activity","volume":"125","author":"Koh","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"15","key":"10.1016\/j.canlet.2021.10.022_bib36","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1182\/blood-2011-01-331181","article-title":"Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC","volume":"118","author":"Nahar","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.canlet.2021.10.022_bib37","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.exphem.2006.06.019","article-title":"A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia","volume":"34","author":"Huang","year":"2006","journal-title":"Exp. Hematol."},{"issue":"7","key":"10.1016\/j.canlet.2021.10.022_bib38","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrc2876","article-title":"Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers","volume":"10","author":"Chi","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.canlet.2021.10.022_bib39","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1158\/2159-8290.CD-15-0754","article-title":"Targeting p300 addiction in CBP-deficient cancers causes synthetic lethality by apoptotic cell death due to abrogation of MYC expression","volume":"6","author":"Ogiwara","year":"2016","journal-title":"Cancer Discov."},{"issue":"7337","key":"10.1016\/j.canlet.2021.10.022_bib40","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature09730","article-title":"Inactivating mutations of acetyltransferase genes in B-cell lymphoma","volume":"471","author":"Pasqualucci","year":"2011","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.canlet.2021.10.022_bib41","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/j.celrep.2018.07.041","article-title":"Enhancer activity requires CBP\/P300 bromodomain-dependent histone H3K27 acetylation","volume":"24","author":"Raisner","year":"2018","journal-title":"Cell Rep."},{"issue":"2","key":"10.1016\/j.canlet.2021.10.022_bib42","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.radonc.2014.03.015","article-title":"C646, a selective small molecule inhibitor of histone acetyltransferase p300, radiosensitizes lung cancer cells by enhancing mitotic catastrophe","volume":"111","author":"Oike","year":"2014","journal-title":"Radiother. Oncol."},{"issue":"8","key":"10.1016\/j.canlet.2021.10.022_bib43","doi-asserted-by":"crossref","first-page":"957","DOI":"10.4161\/epi.6.8.16065","article-title":"Life and death of transcriptional co-activator p300","volume":"6","author":"Chen","year":"2011","journal-title":"Epigenetics"},{"issue":"2","key":"10.1016\/j.canlet.2021.10.022_bib44","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3892\/or.2013.2500","article-title":"Lapatinib inhibits the growth of esophageal squamous cell carcinoma and synergistically interacts with 5-fluorouracil in patient-derived xenograft models","volume":"30","author":"Hou","year":"2013","journal-title":"Oncol. Rep."},{"issue":"7","key":"10.1016\/j.canlet.2021.10.022_bib45","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1158\/1078-0432.CCR-14-1561","article-title":"The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs","volume":"21","author":"Boi","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.canlet.2021.10.022_bib46","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41419-018-0789-1","article-title":"BET bromodomain inhibitor JQ1 preferentially suppresses EBV-positive nasopharyngeal carcinoma cells partially through repressing c-Myc","volume":"9","author":"Li","year":"2018","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.canlet.2021.10.022_bib47","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1158\/1535-7163.MCT-17-0784","article-title":"p110\u03b1 inhibition overcomes stromal cell-mediated Ibrutinib resistance in mantle cell lymphoma","volume":"17","author":"Guan","year":"2018","journal-title":"Mol. Cancer Therapeut."},{"issue":"3","key":"10.1016\/j.canlet.2021.10.022_bib48","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/blood-2016-12-758599","article-title":"Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL","volume":"130","author":"Erdmann","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.canlet.2021.10.022_bib49","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1080\/15592294.2015.1034416","article-title":"Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma","volume":"10","author":"Sengupta","year":"2015","journal-title":"Epigenetics"},{"issue":"11","key":"10.1016\/j.canlet.2021.10.022_bib50","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1158\/1078-0432.CCR-15-2389","article-title":"Molecular pathways: targeting the PI3K pathway in cancer-BET inhibitors to the rescue","volume":"22","author":"Stratikopoulos","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.canlet.2021.10.022_bib51","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/j.celrep.2018.07.055","article-title":"BET inhibition-induced GSK3beta feedback enhances lymphoma vulnerability to PI3K inhibitors","volume":"24","author":"Derenzini","year":"2018","journal-title":"Cell Rep."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521005322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521005322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T16:01:56Z","timestamp":1759593716000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383521005322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":51,"alternative-id":["S0304383521005322"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2021.10.022","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repressing MYC by targeting BET synergizes with selective inhibition of PI3K\u03b1 against B cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2021.10.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}